Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Characterizing Genetic Variation of Adrenergic Signalling Pathways in Takotsubo (Stress) Cardiomyopathy Exomes
Goodloe, Adele H., Evans, Jared M., Middha, Sumit , Prasad, Abhiram , Olson, Timothy M. , Olson, Timothy M , Prasad, Abhiram

European Journal of Heart Failure | August 8, 2014 | Volume: 16 | Issue: 9 | Pages: 942-949

10.1002/ejhf.145 | PMID 25132214 Get It

Abstract Aims Exome sequencing was used to genotype comprehensively a Takotsubo (stress) cardiomyopathy (TC) cohort, enabling investigation of a vast 486 gene network for adrenergic signalling. Methods and results Twenty-eight TC subjects, including a mother–daughter pair and five recurrent cases, underwent whole-exome sequencing. Frequencies of 17 common, functional adrenergic polymorphisms were statistically similar to those of population controls. Filtering for rare, predicted-deleterious, catecholamine/adrenergic signalling variants revealed heterozygosity in 55 genes in TC cases and 59 genes in healthy controls. Overall allele burden was similar and did not discriminate clinical variables among TC subjects, but gene identities were largely cohort specific, and TC cases were enriched for variants within functional domains (68% vs. 48%, P = 0.031). Two-thirds of TC cases carried more than one filtered adrenergic pathway variant, and 11 genes harboured a variant in ≥2 cases. The mother–daughter pair shared missense variants in highly conserved functional domains of ADH5, CACNG1, EPHA4, and PRKCA. An adrenergic pathway-independent analysis of the cohort exposed no common gene for TC. Conclusions Overall, these data support genetic heterogeneity in TC susceptibility and a likely polygenic basis, conferring a cumulative effect on adrenergic pathway dysregulation in a subset of individual subjects. Study of larger cohorts and non-coding regulatory regions is warranted to define genetic risk factors for TC further.
Re: Sarcopenia as a Predictor of Complications and Survival Following Radical Cystectomy
Psutka, Sarah P. , Moynagh, Michael R., Schmit, Grant D. , Tollefson, Matthew K. , Moynagh, Michael, Schmit, Grant, Psutka, Sarah P

Journal of Urology | August 8, 2014 | Volume: 192 | Issue: 5 | Pages: 1582-1583

10.1016/j.juro.2014.05.104 | PMID 25111530 Get It

DRB1*0402 may influence arthritis by promoting naive CD4+T‐cell differentiation in to regulatory T cells
Luckey, David, Behrens, Marshall D., Smart, Michele, Luthra, Harvinder S., David, Chella S., Taneja, Veena , Taneja, Veena

European Journal of Immunology | August 8, 2014 | Volume: 44 | Issue: 11 | Pages: 3429-3438

10.1002/eji.201344424 | PMID 25103892 Get It

HLA‐DRB1*0401 expression in humans has been associated with a predisposition to developing rheumatoid arthritis (RA) and collagen‐induced arthritis (CIA), while HLA‐DRB1*0402 is not associated with susceptibility. Here, we determined if mice transgenic (Tg) for human *0401 have a CD4+ T‐cell repertoire that predetermines proinflammatory cytokine production. The data show that both *0401 and *0402 Tg mice can produce TH1/TH17 cytokines, although the kinetics of response may be different. However, in the context of antigen‐specific responses in a CIA model, *0402 Tg mice generate a TH2 response that may explain their resistance to developing arthritis. In addition, a significant subset of naïve CD4+ T cells from *0402 Tg mice can be activated in polarizing conditions to differentiate into Treg cells that produce IFN‐γ. *0401 Tg mice harbor memory CD4+ T cells that differentiate into IL‐17+ cells in various polarizing conditions. Our data suggest that *0401 Tg mice generate a strong immune response to lipopolysaccharide and may be efficient in clearing infection, and may *0401 have been evolutionarily selected for this ability. Autoimmunity, such as RA, could likely be a bystander effect of the cytokine storm that, along with the presence of low Treg‐cell numbers in *0401 Tg mice, causes immune dysregulation.
Pulmonary Arterial Hypertension in a Patient with β‐Thalassemia Intermedia and Reversal with Infusion Epoprostenol Then Transition to Oral Calcium Channel Blocker Therapy: Review of Literature
Ussavarungsi, Kamonpun , Burger, Charles D.

Pulmonary Circulation | August 7, 2014 | Volume: 4 | Issue: 3 | Pages: 520-526

10.1086/677367 | PMID 25621166 Get It

Pulmonary arterial hypertension (PAH) is a potentially life‐threatening complication of thalassemia. A sexagenarian with β‐thalassemia intermedia presented with new‐onset dyspnea and syncope. Right heart catheterization confirmed severe PAH. Her functional class IV symptoms and severely elevated mean pulmonary artery pressure prompted the initiation of continuous epoprostenol therapy. Clinical follow‐up documented significant improvement in functional class, 6‐minute walk distance, and right ventricular size and function as well as pulmonary arterial pressure on echocardiogram. At the patient's request, epoprostenol was down‐titrated and eventually discontinued. The patient was then safely transitioned to nifedipine therapy after verification of vasoresponsiveness.
Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus , Gram-Negative Bacteria, and Multiple Infections
Aksamit, Timothy R. , Chotirmall, Sanjay H. , Elborn, J.S. , Ranganathan, Sarath , Waters, Valerie J., Ratjen, Félix , Chmiel, James F. , Dasenbrook, Elliott C. , LiPuma, John J. , Waters, Valerie , Ratjen, Felix

Annals of the American Thoracic Society | August 7, 2014 | Volume: 11 | Issue: 7 | Pages: 1120-1129

10.1513/annalsats.201402-050as | PMID 25102221 Get It

Abstract Despite significant advances in treatment strategies targeting the underlying defect in cystic fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part series, we review recent evidence related to the complexity of CF airway infection, explore data suggesting the relevance of individual microbial species, and discuss current and future treatment options. In Part I, the evidence with respect to the spectrum of bacteria present in the CF airway, known as the lung microbiome is discussed. Subsequently, the current approach to treat methicillin-resistant Staphylococcus aureus, gram-negative bacteria, as well as multiple coinfections is reviewed. Newer molecular techniques have demonstrated that the airway microbiome consists of a large number of microbes, and the balance between microbes, rather than the mere presence of a single species, may be relevant for disease pathophysiology. A better understanding of this complex environment could help define optimal treatment regimens that target pathogens without affecting others. Although relevance of these organisms is unclear, the pathologic consequences of methicillin-resistant S. aureus infection in patients with CF have been recently determined. New strategies for eradication and treatment of both acute and chronic infections are discussed. Pseudomonas aeruginosa plays a prominent role in CF lung disease, but many other nonfermenting gram-negative bacteria are also found in the CF airway. Many new inhaled antibiotics specifically targeting P. aeruginosa have become available with the hope that they will improve the quality of life for patients. Part I concludes with a discussion of how best to treat patients with multiple coinfections.
Histopathologic insights into the mechanism of anti‐non‐Gal antibody‐mediated pig cardiac xenograft rejection
Byrne, Guerard W. , Azimzadeh, Agnes M. , Ezzelarab, Mohamed , Tazelaar, Henry D. , Ekser, Burcin , Pierson, Richard N. , McGregor, Christopher G.A. , Ezzelarab, Mohamed B. , Tazelaar, Henry D. , Robson, Simon Christopher , Cooper, David K. C. , Ekser, Burcin

Xenotransplantation | August 7, 2014 | Volume: 20 | Issue: 5 | Pages: 292-307

10.1111/xen.12050 | PMID 25098626 Get It

AbstractThe histopathology of cardiac xenograft rejection has evolved over the last 20 yr with the development of new modalities for limiting antibody‐mediated injury, advancing regimens for immune suppression, and an ever‐widening variety of new donor genetics. These new technologies have helped us progress from what was once an overwhelming anti‐Gal‐mediated hyperacute rejection to a more protracted anti‐Gal‐mediated vascular rejection to what is now a more complex manifestation of non‐Gal humoral rejection and coagulation dysregulation. This review summarizes the changing histopathology of Gal‐ and non‐Gal‐mediated cardiac xenograft rejection and discusses the contributions of immune‐mediated injury, species‐specific immune‐independent factors, transplant and therapeutic procedures, and donor genetics to the overall mechanism(s) of cardiac xenograft rejection.
Comparative Evaluation of Two Commercial Multiplex Panels for Detection of Gastrointestinal Pathogens by Use of Clinical Stool Specimens
Khare, Reeti , Espy, Mark J., Cebelinski, Elizabeth , Boxrud, David, Sloan, Lynne M., Cunningham, Scott A. , Pritt, Bobbi S. , Patel, Robin , Binnicker, Matthew J. , Patel, Robin , Pritt, Bobbi S , Cunningham, Scott A

Journal of Clinical Microbiology | August 7, 2014 | Volume: 52 | Issue: 10 | Pages: 3667-3673

10.1128/jcm.01637-14 | PMID 25100818 Get It

ABSTRACT The detection of pathogens associated with gastrointestinal disease may be important in certain patient populations, such as immunocompromised hosts, the critically ill, or individuals with prolonged disease that is refractory to treatment. In this study, we evaluated two commercially available multiplex panels (the FilmArray gastrointestinal [GI] panel [BioFire Diagnostics, Salt Lake City, UT] and the Luminex xTag gastrointestinal pathogen panel [GPP] [Luminex Corporation, Toronto, Canada]) using Cary-Blair stool samples ( n = 500) submitted to our laboratory for routine GI testing (e.g., culture, antigen testing, microscopy, and individual real-time PCR). At the time of this study, the prototype (non-FDA-cleared) FilmArray GI panel targeted 23 pathogens (14 bacterial, 5 viral, and 4 parasitic), and testing of 200 μl of Cary-Blair stool was recommended. In contrast, the Luminex GPP assay was FDA cleared for the detection of 11 pathogens (7 bacterial, 2 viral, and 2 parasitic), but had the capacity to identify 4 additional pathogens using a research-use-only protocol. Importantly, the Luminex assay was FDA cleared for 100 μl raw stool; however, 100 μl Cary-Blair stool was tested by the Luminex assay in this study. Among 230 prospectively collected samples, routine testing was positive for one or more GI pathogens in 19 (8.3%) samples, compared to 76 (33.0%) by the FilmArray and 69 (30.3%) by the Luminex assay. Clostridium difficile (12.6 to 13.9% prevalence) and norovirus genogroup I (GI)/GII (5.7 to 13.9% prevalence) were two of the pathogens most commonly detected by both assays among prospective samples. Sapovirus was also commonly detected (5.7% positive rate) by the FilmArray assay. Among 270 additional previously characterized samples, both multiplex panels demonstrated high sensitivity (>90%) for the majority of targets, with the exception of several pathogens, notably Aeromonas sp. (23.8%) by FilmArray and Yersinia enterocolitica (48.1%) by the Luminex assay. Interestingly, the FilmArray and Luminex panels identified mixed infections in 21.1% and 13.0% of positive prospective samples, respectively, compared to only 8.3% by routine methods.
Smoking Cessation Among African American and White Smokers in the Veterans Affairs Health Care System
Ryn, Michelle van , Noorbaloochi, Siamak , Clothier, Barbara , Taylor, Brent C , Sherman, Scott E. , Joseph, Anne M. , Fu, Steven S. , Burgess, Diana J. , Burgess, Diana Jill , van Ryn, Michelle

American Journal of Public Health | August 6, 2014 | Volume: 104 | Issue: S4 | Pages: S580-S587

10.2105/ajph.2014.302023 | PMID 25100424 Get It

Objectives. We examined whether a proactive care smoking cessation intervention designed to overcome barriers to treatment would be especially effective at increasing cessation among African Americans receiving care in the Veterans Health Administration. Methods. We analyzed data from a randomized controlled trial, the Veterans Victory over Tobacco study, involving a population-based electronic registry of current smokers (702 African Americans, 1569 Whites) and assessed 6-month prolonged smoking abstinence at 1 year via a follow-up survey of all current smokers. We also examined candidate risk adjustors for the race effect on smoking abstinence. Results. The interaction between patient race and intervention condition (proactive care vs usual care) was not significant. Overall, African Americans had higher quit rates than Whites (13% vs 9%; P < .006) regardless of condition. Conclusions. African Americans quit at higher rates than Whites. These findings may be a result of the large number of veterans receiving smoking cessation services and the lack of racial differences in receipt of these services as well as racial differences in smoking history, self-efficacy, and motivation to quit that favor African Americans.